Iressa v BSC (Best Supportive Care) in First Line NSCLC

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

February 28, 2007

Study Completion Date

April 30, 2016

Conditions
NSCLC
Interventions
DRUG

Gefitinib

OTHER

Placebo

Trial Locations (36)

Unknown

Research Site, Bedford Park

Research Site, Chermside

Research Site, Concord

Research Site, Melbourne

Research Site, Newcastle

Research Site, Prahran

Research Site, Randwick

Research Site, Calgary

Research Site, Edmonton

Research Site, Kelowna

Research Site, Surrey

Research Site, Winnipeg

Research Site, Moncton

Research Site, Halifax

Research Site, Barrie

Research Site, Hamilton

Research Site, Kingston

Research Site, London

Research Site, Mississauga

Research Site, Newmarket

Research Site, Oshawa

Research Site, Ottawa

Research Site, Sault Ste. Marie

Research Site, Thunder Bay

Research Site, Toronto

Research Site, Nová Ves pod Pleší

Research Site, 's-Hertogenbosch

Research Site, Amsterdam

Research Site, Eindhoven

Research Site, The Hague

Research Site, Zutphen

Research Site, Abergavenny

Research Site, Birmingham

Research Site, Cardiff

Research Site, Leeds

Research Site, Wolverhampton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY